Sagimet Biosciences Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Sagimet Biosciences Inc. (SGMT) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 721.08 thousand shares for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-12.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-05-12
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 721.08K shares, a 30.15% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-06-30 was 244.31K shares, a 77.97% decline year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-03-31 was 1.03M shares, a 2582.59% increase year-over-year.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.63M shares, a 177.81% increase from fiscal 2023.
- Sagimet Biosciences Inc. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 585.92K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-03-31 | 721.08K shares 10-Q · filed 2026-05-12 | |||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | 244.31K shares derived: sum of 2 quarters · filed 2025-11-13 | 1.28M shares 10-Q · filed 2025-11-13 | 1.53M shares derived: sum of 4 quarters · filed 2025-11-13 |
| 2025-06-30 | 244.31K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | 1.28M shares 10-Q · filed 2025-08-13 | 1.53M shares derived: sum of 3 quarters · filed 2025-08-13 | 1.76M shares derived: sum of 4 quarters · filed 2025-08-13 |
| 2025-03-31 | 1.03M shares 10-Q · filed 2025-05-08 | 1.28M shares derived: sum of 2 quarters · filed 2025-05-08 | 1.51M shares derived: sum of 3 quarters · filed 2025-05-08 | 2.62M shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 252.44K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-12 | 480.23K shares derived: sum of 2 quarters · filed 2025-03-12 | 1.59M shares derived: sum of 3 quarters · filed 2025-03-12 | 1.63M shares 10-K · filed 2025-03-12 |
| 2024-09-30 | 227.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 1.34M shares derived: sum of 2 quarters · filed 2024-11-14 | 1.38M shares 10-Q · filed 2024-11-14 | 1.38M shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 1.11M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | 1.15M shares 10-Q · filed 2024-08-14 | 1.15M shares derived: sum of 3 quarters · filed 2024-08-14 | |
| 2024-03-31 | 38.48K shares 10-Q · filed 2024-05-15 | 38.48K shares derived: sum of 2 quarters · filed 2024-05-15 | ||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | 585.92K shares 10-K · filed 2024-03-25 | ||
| 2023-09-30 | 585.92K shares 10-Q · filed 2023-11-13 | |||
| 2023-03-31 | 0.00 shares 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |